topotecan has been researched along with Carcinoma in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (18.60) | 18.2507 |
| 2000's | 19 (44.19) | 29.6817 |
| 2010's | 15 (34.88) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, E; Dahmane, N; Garman, T; Hagen, N; Holland, D; Klumpp-Thomas, C; Laramee, M; Martin, B; McKnight, C; Souweidane, M; Thomas, CJ; Wang, A; Wilson, K; Xu, X; Zhang, X | 1 |
| Du, HZ; Gao, YS; Li, RM; Luo, XJ; Qian, CM; Sun, L; Wang, JS; Wei, D; Yu, BY; Yu, XW; Yuan, ST | 1 |
| Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ | 1 |
| Cao, H; Chen, X; Chen, Y; Fan, J; Fu, S; Lin, S; Ren, P; Su, Z; Sun, X; Wu, J; Yang, B; Yang, L; Zhang, Y; Zhou, J; Zhou, Y; Zou, X | 1 |
| Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM | 1 |
| Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Larson, RS; Lovato, DM; Ricci, JW; Severns, V; Sklar, LA | 1 |
| Malpass, TW; McGonigle, KF; Muntz, HG; Robertson, MD; Weiden, PL | 1 |
| Borst, P; de Water, N; Gunnarsdottir, S; Jaspers, JE; Jonkers, J; Kersbergen, A; Nygren, AO; Pajic, M; Rottenberg, S; van der Burg, E; van Tellingen, O; Zander, SA | 1 |
| Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| D'Onofrio, G; Dorio, AS; Fulgione, D; Graziani, G; Malanga, M; Maselli, V; Muzi, A; Quesada, P; Tramontano, F | 1 |
| McGuire, WP | 1 |
| Brotto, L; Casado, A; Cervantes, A; Chen, D; D'Hondt, V; Eisenhauer, EA; Elit, L; Germa, JR; Ghatage, P; Grimshaw, R; Hoskins, P; Katsaros, D; Mendiola, C; Ojeda, B; Oza, A; Poveda, A; Provencher, D; Roy, M; Stuart, G; Sugimoto, A; Tu, D; Vergote, I; Zola, P | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C | 1 |
| Gutierrez, M; Lhomme, C; Pautier, P | 1 |
| Fields, AL; Runowicz, CD | 1 |
| Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV | 1 |
| Edgerton, CC; Gilman, M; Roth, BJ | 1 |
| Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D | 1 |
| Daoud, SS; Mixter, P; Redkar, A | 1 |
| Pavlidis, N; Pentheroudakis, G | 1 |
| Ditto, A; Fanfani, F; Luoni, C; Mariani, L; Oggionni, M; Pilotti, S; Scambia, G; Suardi, S; Zunino, F | 1 |
| Belinson, JL; Michener, CM | 1 |
| Cailliot, C; Dosquet, C; Fabbro, M; Genève, J; Gligorov, J; Goetschel, A; Gosse, B; Lefèvre, G; Lhommé, C; Lokiec, F; Lotz, JP; Micléa, JM; Pautier, P; Provent, S; Ribrag, V; Selle, F; Viens, P; Viret, F | 1 |
| duPont, NC; Monk, BJ | 1 |
| Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W | 1 |
| Carenini, N; Perego, P; Pratesi, G; Romanelli, S; Tortoreto, M; Zunino, F | 1 |
| Cass, I; Fields, AL; Goldberg, GL; Kuo, DY; Runowicz, CD | 1 |
| Abendstein, B; Klingler, PJ; Sevin, BU | 1 |
| Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H | 1 |
| Blaese, RM; Morris, JC; Wildner, O | 1 |
| Engelholm, SA; Nielsen, D; Nielsen, HA | 1 |
| Fluellen, L; Fusco, N; Gordon, NH; Hoppel, CL; Ingalls, ST; Rodriguez, M; Rose, PG | 1 |
| Fleagle, JT; Gordon, AN; Gore, ME; Guthrie, D; Lacave, AJ; Parkin, DE | 1 |
| Bookman, MA | 1 |
8 review(s) available for topotecan and Carcinoma
| Article | Year |
|---|---|
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Current therapies in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Drug Approval; Female; Forecasting; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Topotecan; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Management of leptomeningeal malignancy.
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arachnoid Cysts; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Delayed-Action Preparations; Enzyme Inhibitors; Humans; Injections, Intravenous; Injections, Spinal; Leukemia; Lymphoma; Meningeal Neoplasms; Methotrexate; Palliative Care; Randomized Controlled Trials as Topic; Thiotepa; Topoisomerase I Inhibitors; Topotecan | 2005 |
Chemotherapy in the management of cervical carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Palliative Care; Topotecan; Uterine Cervical Neoplasms | 2006 |
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 1997 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
14 trial(s) available for topotecan and Carcinoma
| Article | Year |
|---|---|
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2015 |
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms | 2015 |
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Female; Humans; Infusions, Parenteral; Middle Aged; Models, Biological; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2010 |
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization | 2004 |
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome | 2004 |
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome | 2008 |
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan | 1996 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome | 1998 |
Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Female; Humans; Middle Aged; Ovarian Neoplasms; Topotecan; Treatment Outcome | 2000 |
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lactones; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan | 2000 |
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Doxorubicin; Female; Humans; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Sickness Impact Profile; Survival Analysis; Topotecan | 2001 |
21 other study(ies) available for topotecan and Carcinoma
| Article | Year |
|---|---|
Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma.
Topics: Animals; Carcinoma; Child; Choroid Plexus Neoplasms; Humans; Mammals; Melphalan; Mice; Topotecan | 2023 |
Synergistic combination of DT-13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC-823 cells via NM IIA/EGFR/HK II axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Drug Synergism; Endocytosis; ErbB Receptors; Female; Glycolysis; Hexokinase; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Nonmuscle Myosin Type IIA; RNA, Small Interfering; Saponins; Stomach Neoplasms; Topotecan; Xenograft Model Antitumor Assays | 2019 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
Topics: Animals; Carcinoma; Cell Hypoxia; Chronotherapy; Combined Modality Therapy; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Histones; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous | 2013 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Ovarian Neoplasms; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genes, p53; Mammary Neoplasms, Animal; Maximum Tolerated Dose; Mice; Mice, Knockout; Phthalazines; Piperazines; Topoisomerase I Inhibitors; Topotecan | 2010 |
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Signal Transduction; Topoisomerase I Inhibitors; Topotecan | 2011 |
Another confirmation of the inactivity of topotecan in ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Female; Humans; International Cooperation; Multicenter Studies as Topic; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan; Treatment Failure | 2010 |
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome | 2002 |
Topotecan-induced bronchiolitis.
Topics: Antineoplastic Agents; Bronchiolitis; Carcinoma; Enzyme Inhibitors; Female; Humans; Middle Aged; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2004 |
Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Epithelial Cells; Female; Genes, p53; Humans; Staurosporine; Topotecan; Tumor Cells, Cultured | 2004 |
p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Topotecan; Treatment Outcome | 2005 |
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan | 2005 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Topics: Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platelet Count; Thrombocytopenia; Topotecan | 1998 |
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Topics: Antineoplastic Agents; Autoantibodies; Carcinoma; Female; Humans; Immunoelectrophoresis; Neoplasm Recurrence, Local; Neurons; Ovarian Neoplasms; Thrombocytopenia; Topotecan | 1998 |
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinogenicity Tests; Carcinoma; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Female; Ganciclovir; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Prodrugs; Simplexvirus; Survival Rate; Thymidine Kinase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |